Wave CMO Christopher Wright reports initial holdings
Wave Life Sciences Ltd. Chief Medical Officer Christopher I. Wright filed an initial ownership report showing his equity position.
Rhea-AI Filing Summary
Wave Life Sciences Ltd. Chief Medical Officer Christopher I. Wright filed an initial ownership report showing his equity position. He holds options over 300,000 ordinary shares at an exercise price of $5.94 expiring on May 27, 2035 and options over 273,750 ordinary shares at $12.75 expiring on February 5, 2036, all held directly. He also directly owns 45,625 ordinary shares. Footnotes explain that these options and restricted share units vest in stages between May 27, 2026 and February 8, 2030, contingent on his continued service with the company.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Wright Christopher I
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 573,750 contracts (Direct);
Ordinary Shares — 45,625 shares (Direct)
Footnotes (3)
- F1. Consists of restricted share units (RSUs). Each RSU represent the right to receive one ordinary share upon vesting. The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.
- F2. The option vests as to 25% of the shares on May 27, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until May 27, 2029, subject to the Reporting Person's continued service through the applicable vesting date.
- F3. The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.
Key Figures
Option underlying shares: 300,000 shares
Option exercise price: $5.94/share
Second option underlying shares: 273,750 shares
+4 more
7 metrics
Option underlying shares
300,000 shares
Share option at $5.94 exercise price, expiring May 27, 2035
Option exercise price
$5.94/share
Share option over 300,000 ordinary shares
Second option underlying shares
273,750 shares
Share option at $12.75 exercise price, expiring February 5, 2036
Second option exercise price
$12.75/share
Share option over 273,750 ordinary shares
Direct ordinary shares
45,625 shares
Ordinary shares held directly following the reported holdings
Option vesting start
25% on May 27, 2026
Vesting schedule for $5.94 options, then 6.25% quarterly until May 27, 2029
Second option vesting start
25% on February 8, 2027
Vesting schedule for $12.75 options, then 6.25% quarterly until February 8, 2030
Key Terms
restricted share units, RSUs, vest, exercise price, +1 more
5 terms
RSUs financial
"Consists of restricted share units (RSUs). Each RSU represent the right to receive one ordinary share upon vesting."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
vest financial
"The option vests as to 25% of the shares on May 27, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price: "5.9400" and "12.7500" for the share options"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Christopher Wright report owning in Wave Life Sciences (WVE)?
Christopher Wright reports direct ownership of 45,625 ordinary shares and two large option positions covering 300,000 and 273,750 ordinary shares. These positions represent his equity stake as Chief Medical Officer, combining current share ownership with substantial future purchase rights.
What are the exercise prices of Christopher Wright’s Wave Life Sciences (WVE) options?
He holds options over 300,000 ordinary shares at an exercise price of $5.94 and options over 273,750 ordinary shares at $12.75. These prices define the cost per share he must pay if he chooses to exercise the options in the future.
When do Christopher Wright’s Wave Life Sciences (WVE) options expire?
His $5.94 exercise price options expire on May 27, 2035, and his $12.75 options expire on February 5, 2036. These long-dated expirations give him many years to meet vesting conditions and decide whether to exercise his rights.
How do Christopher Wright’s Wave Life Sciences (WVE) equity awards vest over time?
The footnotes state his options generally vest 25% on a specified first anniversary date, then 6.25% quarterly until fully vested. Related RSUs vest in four equal annual installments from February 8, 2027 through February 8, 2030, subject to continued service.
Does this Wave Life Sciences (WVE) Form 3 show any insider buying or selling?
The Form 3 lists Christopher Wright’s existing holdings and option grants but does not report any explicit purchases or sales. It functions as an initial ownership snapshot rather than a record of new market transactions in Wave Life Sciences shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
